⌕
Arbutus Biopharma · ABUS · Nasdaq
Tenet 49 · Mixed
Compare
$4.14+1.10%Market openTenet 49 · Mixed
$4.14+0.05 (+1.10%)
Market open · 15-min delayed · as of 10:09 AM ET· Nasdaq · USD

Arbutus Biopharma (ABUS) Stock Checks

How ABUS measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

2 / 17 qualify todayas of close, Nov 16, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
2
meet every gate today
BORDERLINE
2
within one input of the gate
FAILS
10
miss at least one gate
UNKNOWN
3
insufficient data to judge
Buffett Qualitydurable moat
~ Borderline
PassesROE ≥ 15%(TTM through Sep 30, 2026)269.6% · ≥ 15.0%
PassesGross margin ≥ 40%(TTM through Sep 30, 2026)100.0% · ≥ 40.0%
Unknown — no dataNet margin ≥ 15%— · ≥ 15.0%
PassesDebt/equity ≤ 0.5(quarter ending Sep 30, 2026)0.00 · ≤ 0.50
FailsGrowing FCF (multi-yr)Free cash flow was negative in fiscal 2025.no · > 0
Decided by the pass rule for Buffett Quality.
The pass rule for Buffett Quality is what decides that verdict, and it is not restated here. 1 of 5 carry no data.Buffett Quality under The screens ›Today's Buffett Quality list ›
FailsReturn on assets positive(fiscal 2025)−35.4% · > 0
FailsOperating cash flow positive(fiscal 2025)−$39.6M · > 0
PassesReturn on assets improving(fiscal 2025)−53.1% → −35.4%
FailsEarnings backed by cash (CFO > net income)(fiscal 2025)−$39.6M vs −$33.5M
FailsLeverage falling (long-term debt / assets)(fiscal 2025)We hold no record of long-term debt as a share of assets for both years for this company, so this signal could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.no
PassesCurrent ratio improving(fiscal 2025)8.15 → 15.73
FailsNo share dilution (≤ +2%)(fiscal 2025)+3.2%
FailsGross margin expanding(fiscal 2025)100.0% → 100.0%
PassesAsset turnover improving(fiscal 2025)0.05 → 0.15
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here. These checks score 3 of 9. 1 of 9 carry no data.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
PassesROIC ≥ 15%(TTM through Sep 30, 2026)171.6% · ≥ 15.0%
Unknown — no dataNet debt/EBITDA ≤ 3×— · ≤ 3.0×
FailsAltman Z ≥ 3 (safe zone)(TTM through Sep 30, 2026)−0.98 · ≥ 3.00
Decided by the pass rule for Munger Compounders.
The pass rule for Munger Compounders is what decides that verdict, and it is not restated here. 1 of 3 carry no data.Munger Compounders under The screens ›Today's Munger Compounders list ›
PassesEBIT > 0(TTM through Sep 30, 2026)$147.2M · > 0
PassesEarnings yield EBIT/EV ≥ 6%(TTM through Sep 30, 2026)50.8% · ≥ 6.0%
PassesReturn on capital ≥ 25%(TTM through Sep 30, 2026)150.7% · ≥ 25.0%
Decided by the pass rule for Magic Formula.
The pass rule for Magic Formula is what decides that verdict, and it is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
FailsSize: market cap ≥ $2B$627.0M · ≥ $2.0B
FailsCurrent ratio ≥ 2(quarter ending Sep 30, 2026)1.40 · ≥ 2.00
FailsPositive EPS 10y0y
FailsPays a dividend$0.00 · > 0
Unknown — no dataEPS growth ≥ 3%/yr— · ≥ 3.0%
PassesP/E ≤ 15(the vendor's trailing twelve months: trailing figures for Healthcare are still under review)2.85 · ≤ 15.00
PassesP/E × P/B ≤ 22.5(trailing twelve months)20.85 · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here. 1 of 7 carry no data.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
Unknown — no dataEPS growth 10–30%— · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout— · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
FailsReturn on invested capital ≥ 15% in 4+ of the last 5 years0 of 3 on file
PassesRevenue compounding ≥ 8%/yr over 5 years15.3% per year · ≥ 8.0%
FailsNot diluting: diluted share count flat-to-down (≤ +1%/yr)18.6% · ≤ 1.0%
FailsFree cash flow margin ≥ 12%−281.5% · ≥ 12.0%
PassesEarnings backed by cash (operating cash flow ≥ net income)1.00 · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check18.6%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
PassesOff its 52-week high by 8–35% (a dip, not a collapse)25.0% · 8.0%–35.0%
FailsDip within its own normal pullback band0.31
PassesNot past where its dips have historically recovered from1.22
FailsA dip in an uptrend (above a rising 200-day)4.48
FailsHigher-low structure still intactstructure broken · no higher low
Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page. 1 of 6 carry no data.
PassesA bullish MACD cross within 10 sessions1.00 · ≤ 10.00
FailsReclaimed a rising 50-day EMA4.31
FailsPrinted a higher lowno
FailsA volume thrust on the turn (≥ 1.2× normal)0.97 · ≥ 1.20
FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)1.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page.
FailsIn the cheap half of its own 5-year valuation range(through fiscal 2025)1.0×
FailsEarnings estimates not being cut−0.01
PassesReturns on capital not deteriorating−0.35
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page.
PassesOperating profit is positive(TTM through Sep 30, 2026)$147.2M · > 0
PassesReturn on invested capital ≥ 10%(TTM through Sep 30, 2026)171.6% · ≥ 10.0%
Not scored: see the reason belowA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)(TTM through Sep 30, 2026)Net debt / EBITDA cannot be read over non-positive EBITDA: the ratio flips sign, so a net-cash company prints a healthy-looking positive. Only the Altman Z half, shown beside this line, is measurable, so the test is left unscored rather than counted either way.−1.0×
PassesQuality score ≥ 5051.80 · ≥ 50.00
PassesRevenue growing over 5 years(fiscal 2020 to 2025)15.3% per year · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
A research signal from published criteria, not a recommendation.
FailsDrawdown context25.0% off its 52-week high
FailsReversal evidence1 of 4 signals fired
FailsTrap gate1 of 3 held
PassesQuality floor4 of 5 held · 1 no data
Invalidation level (structure break): below this the dip's structure has broken$4.29
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here.Qualified Dip under The screens ›Today's Qualified Dip list ›
FailsTrading above its 50-day average4.46
FailsTrading above its 200-day average4.48
Fails50-day average above the 200-day (uptrend stack)4.46
Fails50-day average sloping up−0.07 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Fails3-month return in the top half of the universe0.33 · ≥ 0.50
Fails12-minus-1 momentum in the top half of the universe0.29 · ≥ 0.50
FailsRelative strength vs the S&P 500 improving−0.01 · > 0
FailsEarnings estimates being revised up−0.01
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
PassesMACD above its signal line−0.15
FailsBack above the 50-day on a fresh cross (≤10 sessions)1.00
FailsHigher high and higher low (stair-stepping up)no higher high · no higher low
FailsA volume thrust on the move (≥ 1.2× normal)0.97 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page.
Average daily swing: elevated0.05
Volatility band width: mid-range0.75
Distance from its 52-week high: mid-range0.25
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Arbutus Biopharma pass?

Arbutus Biopharma qualifies on 2 of 17 rule sets as of 2026-11-16, with 2 borderline and 10 failing.

Does Arbutus Biopharma meet the Graham Defensive criteria?

Arbutus Biopharma fails the Graham Defensive rule set as of 2026-11-16.

Does Arbutus Biopharma meet the Buffett Quality criteria?

Arbutus Biopharma is borderline on the Buffett Quality rule set as of 2026-11-16.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.